NDC 50222-346

Adbry

Tralokinumab-ldrm

Adbry is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Leo Pharma Inc.. The primary component is Tralokinumab.

Product ID50222-346_078bc388-36dc-4b6e-bb32-ccdafcc39128
NDC50222-346
Product TypeHuman Prescription Drug
Proprietary NameAdbry
Generic NameTralokinumab-ldrm
Dosage FormInjection, Solution
Route of AdministrationSUBCUTANEOUS
Marketing Start Date2022-01-02
Marketing CategoryBLA /
Application NumberBLA761180
Labeler NameLEO Pharma Inc.
Substance NameTRALOKINUMAB
Active Ingredient Strength150 mg/mL
Pharm ClassesInterleukin-13 Antagonist [EPC], Interleukin-13 Antagonists [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 50222-346-02

2 SYRINGE, GLASS in 1 CARTON (50222-346-02) > 1 mL in 1 SYRINGE, GLASS (50222-346-01)
Marketing Start Date2022-01-02
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [Adbry]

Mark Image

Registration | Serial
Company
Trademark
Application Date
ADBRY
ADBRY
90803235 not registered Live/Pending
LEO Pharma A/S
2021-06-30

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.